| Biomarker ID | 26 |
| PMID | 11489752 |
| Year | 2001 |
| Biomarker | Insulin Like Growth Factor Binding Protein 3 (IGFBP-3) |
| Biomarker Basis | Concentration Based (ng/ml) |
| Biomolecule | Protein |
| Source | Plasma |
| Subjects | Humans |
| Regulation | Dowregulated (Preintervention: 5230 ± 244 ng/mL Vs Postintervention: 3924 ± 298 ng/mL) |
| Odds Ratio/Hazard Ratio/Relative Risk | NA |
| Effect on Pathways | Pathways Include:-Hypoxia and p53 in the cardiovascular system,Insulin-like growth factor (IGF) activity regulation by insulin-like growth factor binding proteins (IGFBPs),TAp63 pathway,Delta Np63 pathway,Ghrelin-mediated regulation of food intake and energy homeostasis |
| Experiment | Prostate Cancer patients pre and post treatment with Lycopene |
| Type of Biomarker | Predictive |
| Cohort | 13 patients with prostate cancer were treated with Lycopene for this study. 10 controls were included. |
| Senstivity | NA |
| Specificity | NA |
| AUC | NA |
| Accuracy | NA |
| Level Of Significance | p=0.0002 |
| Method Used | ELISA |
| Clinical | Yes |
| Remarks | Effect of Lycopene treatment on Biomarkers Connexin 43, bcl-2, bax, IGI-1, IGFPB3-3. First 3 markers were not statstically significant. |
| Clinical Trial Number | NA |
| Degree Of Validity | Not validated on independent patient dataset |
| Technical Name | IGFBP3 |